2014-04-29 16:00Financial Performance - The company's operating revenue for Q1 2014 was RMB 1,227,854,663.29, representing a 16.31% increase compared to RMB 1,055,640,495.32 in Q1 2013[12] - Net profit attributable to shareholders decreased by 2.31% to RMB 143,350,797.52 from RMB 146,739,417.67 in the same period last year[12] - The net profit after deducting non-recurring gains and losses was RMB 127,378,556.04, down 8.21% from RMB 138,769,476.60 in Q1 2013[12] - The basic earnings per share for Q1 2014 was RMB 0.48, a decrease of 4.00% compared to RMB 0.50 in Q1 2013[12] - The weighted average return on equity was 4.20%, down 0.56 percentage points from 4.76% in the previous year[12] - The company reported a net profit of 4,476,582.24 RMB for the reporting period, with a loss of 561,734.79 RMB impacting the consolidated net profit[31] - The company has not experienced significant changes in net profit compared to the previous year[30] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 249.53% to RMB 170,050,402.52, compared to RMB 48,651,126.55 in the previous year[12] - Total assets as of March 31, 2014, reached RMB 7,131,952,969.68, an increase of 8.62% from RMB 6,566,006,124.91 at the end of 2013[12] - The net assets attributable to shareholders increased by 4.26% to RMB 3,487,062,608.76 from RMB 3,344,648,576.49 at the end of 2013[12] - The company's cash and cash equivalents increased by 46.59% to RMB 1,115,608,739.96 due to an increase in short-term borrowings[21] - The cash received from investment activities decreased by 100% to RMB 0, as there were no asset sales during the reporting period[24] Borrowings and Financial Expenses - Short-term borrowings rose by 71.25% to RMB 840,993,530.73, indicating increased bank loans during the reporting period[21] - The financial expenses surged by 388.34% to RMB 10,192,562.95 primarily due to foreign exchange losses and increased interest expenses[22] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,878, with 9,876 being A-share shareholders[17] - The largest shareholder, Hong Kong Central Clearing Limited, held 37.87% of the H shares, totaling 111,993,254 shares[17] Government Subsidies and Sales Revenue - The company received government subsidies amounting to RMB 20,303,264.42, reflecting a 178.47% increase compared to the previous period[22] - Sales revenue from goods and services received cash increased by 39.21% to RMB 1,375,047,811.57, attributed to higher sales collections[23] Asset Impairment and Investments - The company reported a 342.19% increase in asset impairment losses to RMB 14,086,940.21, mainly due to increased inventory write-downs[22] - The company holds 1,000,000 shares of Kunlun Energy, with a market value of 10,293,789.00 RMB, representing 94.75% of the total securities investment[30] - The company has a total investment of 2,490,030.86 RMB in other listed companies, with a total book value of 9,857,078.24 RMB[33] - The company has no derivative investments during the reporting period[34] Corporate Commitments and Compliance - The company reported a commitment to not engage in any competitive business related to its pharmaceutical research, development, production, and sales[27] - The commitment includes a priority right for the company to acquire any new business opportunities that may compete with its existing operations[27] - The company will provide annual confirmations regarding compliance with the commitment terms to be included in its annual report[28] - The commitment will terminate if the company ceases to be the controlling shareholder or if its shares are delisted from the stock exchange[28] - The company has agreed to allow independent directors to review compliance with the commitment at least once a year[28] - The company will notify the relevant parties immediately if any pledged shares are to be sold[28] - The company has committed to not sell its shares during the first six months post-listing without prior approval[28] - The company will not establish any rights or interests that would result in it no longer being the controlling shareholder within 12 months post-listing[28] - The company is focused on maintaining shareholder rights and ensuring compliance with regulatory requirements[27] - The company has outlined specific legal responsibilities in case of any violations of the commitment terms[28] Share Transition and Investor Engagement - The company completed the conversion of B shares to H shares on January 16, 2014, enhancing its international image and financing capabilities[25] - The company is in the process of transitioning from B shares to H shares, with commitments made to avoid competition during this process[29] - The company has engaged with various institutional investors regarding its business direction and operational status[35] - The company plans to disclose any significant share reductions by its major shareholder, Health元, in advance of such transactions[29] - The company has not reported any securities sold during the reporting period[31] - The company has committed to maintaining its shareholding until the B to H share conversion is completed[29]